Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model

Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model

BackgroundPatients with stable coronary artery disease (CAD) constitute a heterogeneous group in which the treatment benefits by angiotensin‐converting enzyme (ACE)‐inhibitor therapy vary between individuals. Our objective was to integrate clinical and pharmacogenetic determinants in an ultimate com...

Full description

Bibliographic Details
Main Authors: Rohit M. Oemrawsingh, K. Martijn Akkerhuis, Laura C. Van Vark, W. Ken Redekop, Goran Rudez, Willem J. Remme, Michel E. Bertrand, Kim M. Fox, Roberto Ferrari, A.H. Jan Danser, Moniek de Maat, Maarten L. Simoons, Jasper J. Brugts, Eric Boersma
Format: Article
Language:English
Published: Wiley 2016-03-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
angiotensin‐converting enzyme inhibitor
coronary artery disease
individualized therapy
pharmacogenetics
risk model
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.115.002688

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.115.002688

Similar Items